Edition:
India

Galapagos NV (GLPG.OQ)

GLPG.OQ on NASDAQ Stock Exchange Global Select Market

99.48USD
15 Jun 2018
Change (% chg)

$-3.48 (-3.38%)
Prev Close
$102.96
Open
$101.39
Day's High
$101.50
Day's Low
$99.48
Volume
40,588
Avg. Vol
38,759
52-wk High
$121.08
52-wk Low
$72.92

Latest Key Developments (Source: Significant Developments)

ProQR And Galapagos Announce Research Collaboration
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Galapagos Nv ::PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY.PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS.PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED.  Full Article

Galapagos NV reports Q3 loss of ‍1.75​ euro per share
Friday, 27 Oct 2017 

Oct 26 (Reuters) - Galapagos NV -:Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​.Galapagos NV qtrly loss per share ‍1.75​ euro.Galapagos NV says ‍we anticipate cash burn for full year to be at lower end of guidance of euro 135 million - 155 million​.  Full Article

Galapagos gets orphan drug designation in EU for GLPG1690 in idiopathic pulmonary fibrosis
Tuesday, 6 Sep 2016 

Galapagos NV :Orphan drug designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis.  Full Article

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

No consensus analysis data available.